Wird geladen...
Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
PURPOSE: Conivaptan is an intravenous dual V(1A)/V(2) vasopressin antagonist approved for the treatment of euvolemic and hypervolemic hyponatremia. Earlier studies showed that patients with moderate liver disease could be safely treated with conivaptan by reducing the dose by 50%, whereas patients w...
Gespeichert in:
| Veröffentlicht in: | Drug Des Devel Ther |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315214/ https://ncbi.nlm.nih.gov/pubmed/28243060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S125459 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|